Journey Strategic Wealth LLC Has $1.08 Billion Stake in Johnson & Johnson (NYSE:JNJ)

Journey Strategic Wealth LLC cut its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,881,849 shares of the company’s stock after selling 394,425 shares during the period. Johnson & Johnson makes up 50.8% of Journey Strategic Wealth LLC’s portfolio, making the stock its largest position. Journey Strategic Wealth LLC owned 0.29% of Johnson & Johnson worth $1,078,661,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in JNJ. Dock Street Asset Management Inc. increased its position in shares of Johnson & Johnson by 25.9% during the third quarter. Dock Street Asset Management Inc. now owns 3,276 shares of the company’s stock valued at $510,000 after buying an additional 674 shares during the period. Perfromance Wealth Partners LLC increased its position in shares of Johnson & Johnson by 1.3% during the third quarter. Perfromance Wealth Partners LLC now owns 53,086 shares of the company’s stock valued at $8,268,000 after buying an additional 660 shares during the period. SC&H Financial Advisors Inc. increased its position in shares of Johnson & Johnson by 5.1% during the third quarter. SC&H Financial Advisors Inc. now owns 2,149 shares of the company’s stock valued at $335,000 after buying an additional 105 shares during the period. Choate Investment Advisors increased its position in shares of Johnson & Johnson by 13.6% during the third quarter. Choate Investment Advisors now owns 90,366 shares of the company’s stock valued at $14,075,000 after buying an additional 10,822 shares during the period. Finally, Strengthening Families & Communities LLC increased its position in shares of Johnson & Johnson by 6.9% during the third quarter. Strengthening Families & Communities LLC now owns 15,243 shares of the company’s stock valued at $2,374,000 after buying an additional 981 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

JNJ traded down $1.27 during trading on Thursday, hitting $152.23. The company’s stock had a trading volume of 830,891 shares, compared to its average volume of 7,287,731. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The firm has a market cap of $366.37 billion, a PE ratio of 9.57, a P/E/G ratio of 2.51 and a beta of 0.55. The business’s 50 day simple moving average is $151.73 and its 200-day simple moving average is $155.11.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same period last year, the firm earned $2.68 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. The ex-dividend date is Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.26%. Johnson & Johnson’s dividend payout ratio is 30.92%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Bank of America cut their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, May 6th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Get Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.